Journey Medical

FDA approves minocycline (Emrosi) for rosacea in adults, offering a new treatment option for pimple-like bumps. Emrosi, a once-daily oral capsule, reduces swelling and inflammation with extended-release technology. Available in the U.S. by late 2024 or early 2025, it was found more effective than current standard care and placebo in clinical trials. Common side effects include indigestion, and caution is advised for sun exposure, pregnancy, and children under 8.

FDA approves Journey Medical's Emrosi (minocycline hydrochloride) for rosacea treatment in adults, based on successful phase 3 trials. Emrosi outperformed Oracea and placebo in reducing inflammatory lesions. Journey Medical plans to launch Emrosi as a new standard of care in 2025.

Beam Therapeutics reports a patient death in BEAM-101 trial for sickle cell disease, unrelated to the therapy. Sana Biotechnology refocuses on autoimmune assets, reducing workforce. Ring Therapeutics expands in Singapore with new deals. Drug regulators criticized for ignoring forced labor in supply chains. OSE Therapeutics' IL-7 therapy shows positive results in ulcerative colitis trial. Japan's PMDA opens second overseas office in Washington.

Journey Medical's Emrosi, approved by the FDA, offers a new treatment for rosacea, showing superiority in Phase III trials over current treatments. Set for U.S. launch in 2025, it aims to become a standard oral care option. Journey Medical also collaborates with Dr. Reddy’s for DFD-29's development and commercialization in specific markets.

Journey Medical receives FDA approval for Emrosi, a 40 mg minocycline hydrochloride extended-release capsule for treating rosacea. Developed with Dr. Reddy’s Laboratories, Emrosi outperformed current standard care and placebo in Phase 3 trials, with no major safety concerns. Expected to launch in late Q1 or early Q2 of 2025, Journey Medical aims to position Emrosi as a new standard of care for adult rosacea patients.

Journey Medical's Emrosi, a new minocycline hydrochloride capsule, has received FDA approval for treating rosacea's inflammatory lesions in adults. Despite concerns over the lack of a redness reduction claim and competition from generic Oracea, Journey's CEO Claude Maraoui anticipates Emrosi's strong market position and potential $300 million annual sales, with a launch planned for Q1-Q2 2025.

FDA approves minocycline hydrochloride extended-release capsules (Emrosi) for rosacea treatment in adults, based on positive phase 3 trial data. Emrosi showed higher efficacy and tolerability compared to standard treatment and placebo, with no significant adverse effects. Journey Medical plans to commercialize Emrosi in the US by Q1-Q2 2024.

FDA approves Journey Medical's Emrosi, a 40mg minocycline hydrochloride extended-release capsule, for rosacea treatment. Developed with Dr Reddy's Laboratories, Emrosi met all co-primary and secondary endpoints in Phase III trials, outperforming placebo and Galderma's Oracea. Journey Medical aims to establish Emrosi as a new standard of care, with initial US market supply expected in H1 2025. This move challenges Galderma's dominance in the rosacea market, as highlighted by GlobalData's 2022 report.

FDA approved minocycline hydrochloride extended-release capsules (DFD-29, Emrosi) for rosacea treatment, supported by successful phase 3 trials MVOR-1 and MVOR-2. DFD-29 showed significant superiority over placebo and doxycycline in reducing inflammatory lesions and achieving IGA success.